Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Chief Technical Officer | February 03, 2025 | February 05, 2025 |
| CERUS CORPCERS · Entity 5431 | Director | June 03, 2025 | June 04, 2025 |
| Instil Bio, Inc.TIL · Entity 7177 | Chief Operating Officer | September 06, 2022 | September 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date February 03, 2025 · Filed February 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,713 |
Reported balance
After 2025-02-03 transaction · row 1
1 source rowRow 1 · 2025-02-03 · Sale · Disposed 14,746 · Balance 250,713 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.715, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.715, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above.
CERUS CORP
Report date June 03, 2025 · Filed June 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,073 |
Reported balance
After 2025-06-03 transaction · row 1
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 60,000 · Balance 205,073 F1: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Instil Bio, Inc.
Report date September 06, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2032-09-05 | Direct | 750,000 |
Reported balance
After 2022-09-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-06 · Grant · Acquired 750,000 · Balance 750,000 F1: Twenty-five percent (25%) of the shares subject to the option vest on September 6, 2023, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to the option vest on September 6, 2023, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 44,943 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Kite Pharma, Inc.
Report date October 03, 2017 · Filed October 05, 2017
Section 16 reporting ended · disclosed 2017-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-10-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-10-03 · Other · Disposed 3,927 · Balance 41,734 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes. Row 2 · 2017-10-03 · Disposition to issuer · Disposed 41,734 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.91 · Expires 2026-03-14 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-03 · Disposition to issuer · Disposed 124,125 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F5: This option provided for 25% vesting on March 15, 2017, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.91 · Expires 2026-03-14 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-03 · Disposition to issuer · Disposed 96,875 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5: This option provided for 25% vesting on March 15, 2017, and vesting thereafter in 36 equal monthly installments. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.09 · Expires 2026-12-21 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-03 · Disposition to issuer · Disposed 30,700 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person.
F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").
F5: This option provided for 25% vesting on March 15, 2017, and vesting thereafter in 36 equal monthly installments.
F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option.
F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio.
F8: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:57 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 44,943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418316 · ownership.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 8,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012470 · wk-form4_1772146515.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,943 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026 Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 22:48 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081864 · ownership.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,073 F1 · shares: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 6,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014189 · wk-form4_1742512140.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,773 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 16:14 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 14,746 | $1.71 | $25,215.66 |
DisclosureSEC source: 0001737287-25-000018 · wk-form4_1738790068.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,713 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.715, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 23:57 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 40,000 | $5.00 | $200,000.00 |
DisclosureSEC source: 0001209191-24-005822 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,073 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 16:18 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | Tax withholdingCommon Stock | 17,360 | $3.47 | $60,188.86 |
DisclosureSEC source: 0001593968-24-000614 · primary_01.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,459 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.44 to $3.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 11,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010744 · wk-form4_1710294203.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,897 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| January 25, 2024 Filed Jan 31, 2024 17:51 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 341,515 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001593968-24-000197 · primary_01.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,515 Underlying: Common Stock · 341,515 shares Expires 2034-01-25 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| January 25, 2024 Filed Jan 31, 2024 17:51 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 96,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000197 · primary_01.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,819 Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-036778 · wk-form4_1699045777.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,633 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document |
| October 01, 2023 Filed Oct 10, 2023 21:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-034204 · wk-form4_1696973174.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,138 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:10 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 40,000 | $5.00 | $200,000.00 |
DisclosureSEC source: 0001209191-23-035763 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,073 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 17:20 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 831,024 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001593968-23-000643 · primary_01.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,024 Underlying: Common Stock · 831,024 shares Expires 2033-04-24 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on April 24, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 17:20 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 186,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-000643 · primary_01.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,219 Read SEC document |
| January 03, 2023 Filed Jan 19, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 10,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-001266 · rdgdoc.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| September 06, 2022 Filed Sep 6, 2022 17:41 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001789769-22-000081 · wf-form4_166250048300587.xml · derivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2032-09-05 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on September 6, 2023, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 7,589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021929 · rdgdoc.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,589 F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and fully vests on the first anniversary of the grant date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:12 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 39,866 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001209191-22-034204 · doc4.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,866 Underlying: Common Stock · 39,866 shares Expires 2032-05-31 F3 · price: Not applicable. F2 · derivative.exercise_date: The option shall vest one year from the date of grant. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:12 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 20,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034204 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,073 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| September 05, 2021 Filed Sep 8, 2021 21:07 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 4,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-055169 · doc4.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,296 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. Read SEC document |
| September 05, 2021 Filed Sep 8, 2021 21:07 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 4,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-055169 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 00:02 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 29,983 | Not disclosed Strike: $5.62 | Not disclosed |
DisclosureSEC source: 0001209191-21-037964 · doc4.xml · derivative · entry 4 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983 Underlying: Common Stock · 29,983 shares Expires 2031-06-01 F4 · price: Not applicable. F5 · derivative.exercise_date: The option shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2022 Annual Meeting of Stockholders. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 00:02 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 14,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037964 · doc4.xml · nonDerivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,323 F2 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:02 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 13,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037964 · doc4.xml · derivative · entry 3 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,228 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. F4 · price: Not applicable. F3 · derivative.exercise_date: This RSU vested one year from the date of grant. F3 · derivative.expiration_date: This RSU vested one year from the date of grant. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 00:02 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 13,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037964 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| September 05, 2020 Filed Sep 8, 2020 21:57 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 4,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-049767 · doc4.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,296 Underlying: Common Stock · 4,296 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. Read SEC document |
| September 05, 2020 Filed Sep 8, 2020 21:57 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 4,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-049767 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:50 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 13,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034821 · doc4.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,228 Underlying: Common Stock · 13,228 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The Restricted Stock Unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. F4 · derivative.expiration_date: The Restricted Stock Unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:50 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 28,177 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001209191-20-034821 · doc4.xml · derivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,177 Underlying: Common Stock · 28,177 shares Expires 2030-06-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The Option shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 22:54 UTC | CERUS CORP CERS · Entity 5431 | PurchaseCommon Stock | 3,614 | $4.75 | $17,165.05 |
DisclosureSEC source: 0001209191-20-009371 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911 F1 · price: The reported price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.745 to $4.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the aforementioned range set forth. Read SEC document |
| January 29, 2020 Filed Feb 4, 2020 01:21 UTC | CERUS CORP CERS · Entity 5431 | PurchaseCommon Stock | 3,614 | $4.15 | $14,998.10 |
DisclosureSEC source: 0001209191-20-006144 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911 Read SEC document |
| January 29, 2020 Filed Feb 13, 2020 22:48 UTC Amendment | CERUS CORP CERS · Entity 5431 | PurchaseCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009369 · doc4a.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,297 F1 · ownership.direct: Amending to reverse purchase transaction that did not consummate. Read SEC document |
| September 05, 2019 Filed Sep 10, 2019 19:01 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 4,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049001 · doc4.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,592 Underlying: Common Stock · 4,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. Read SEC document |
| September 05, 2019 Filed Sep 10, 2019 19:01 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 4,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049001 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:34 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 11,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-035556 · doc4.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,184 Underlying: Common Stock · 11,184 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit shall vest one year from the date of grant. F4 · derivative.expiration_date: The restricted stock unit shall vest one year from the date of grant. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:34 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 23,703 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-19-035556 · doc4.xml · derivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,703 Underlying: Common Stock · 23,703 shares Expires 2029-06-04 F2 · price: Not applicable. F1 · derivative.exercise_date: The option shall vest one year from the date of grant. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 22:52 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Units · Derivative | 12,889 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-050143 · doc4.xml · derivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,889 Underlying: Common Stock · 12,889 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the transaction date. F4 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the transaction date. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 22:52 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 24,324 | Not disclosed Strike: $7.52 | Not disclosed |
DisclosureSEC source: 0001209191-18-050143 · doc4.xml · derivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,324 Underlying: Common Stock · 24,324 shares Expires 2028-09-04 F2 · price: Not applicable. F1 · derivative.exercise_date: The option shall vest in thirty six (36) equal monthly installments on each monthly anniversary of the transaction date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 30,700 | Not disclosed Strike: $46.09 | Not disclosed |
DisclosureSEC source: 0001209191-17-056223 · doc4.xml · derivative · entry 5 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,700 shares Expires 2026-12-21 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8 · derivative.exercise_date: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 96,875 | Not disclosed Strike: $44.91 | Not disclosed |
DisclosureSEC source: 0001209191-17-056223 · doc4.xml · derivative · entry 4 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,875 shares Expires 2026-03-14 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5 · derivative.exercise_date: This option provided for 25% vesting on March 15, 2017, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 124,125 | $135.09 Strike: $44.91 | $16,768,046.25 |
DisclosureSEC source: 0001209191-17-056223 · doc4.xml · derivative · entry 3 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,125 shares Expires 2026-03-14 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F5 · derivative.exercise_date: This option provided for 25% vesting on March 15, 2017, and vesting thereafter in 36 equal monthly installments. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Disposition to issuerCommon Stock | 41,734 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-056223 · doc4.xml · nonDerivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3 · shares: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4 · shares: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). F4 · price: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:17 UTC | Kite Pharma, Inc. KITE · Entity 172664 | OtherCommon Stock | 3,927 | $180.00 | $706,860.00 |
DisclosureSEC source: 0001209191-17-056223 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,734 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:42 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 4,228 | $179.66 | $759,618.97 |
DisclosureSEC source: 0001209191-17-054198 · doc4.xml · nonDerivative · entry 3 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,661 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:42 UTC | Kite Pharma, Inc. KITE · Entity 172664 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-054198 · doc4.xml · nonDerivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,889 Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 19:50 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $44.91 | $0.00 |
DisclosureSEC source: 0001209191-17-047796 · doc4.xml · derivative · entry 4 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Stock · 6,000 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the 155,000 shares subject to the stock option vested and became exercisable on March 15, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 19:50 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 5,131 | $110.05 | $564,666.55 |
DisclosureSEC source: 0001209191-17-047796 · doc4.xml · nonDerivative · entry 3 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 19:50 UTC | Kite Pharma, Inc. KITE · Entity 172664 | SaleCommon Stock | 869 | $110.10 | $95,676.90 |
DisclosureSEC source: 0001209191-17-047796 · doc4.xml · nonDerivative · entry 2 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,531 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 19:50 UTC | Kite Pharma, Inc. KITE · Entity 172664 | Exercise / conversionCommon Stock | 6,000 | $44.91 | $269,460.00 |
DisclosureSEC source: 0001209191-17-047796 · doc4.xml · nonDerivative · entry 1 MOORE TIMOTHY L. · CIK 0001669207 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.